Personal Finance

ncstockguy · Guest

With new information coming out each day on the growing threat of Avian
Influenza, it is worth holding some of the companies that have the most
promising antiviral research.
The one I believe has the best likelihood of a huge run up is AVII.
Do your homework, check the updates on AVII results against ebola and
marburg.
FYI

Rip · Guest

Bcrx I bought into at 12 something. Had a big run up to 17. Decided to
hold instead of selling but the company I looked at when I first tryed
to by some bird flu stocks. I'm up for some suggestions on this. Was
wondering what everyones thoughts on Pfizer which is selling relativly
descent price. Do you think they might be a descent stock to buy.

Guest · Posted: Sun Nov 13, 2005 1:00 am Post subject: Re: Avian Flu biotechs

Major article on AVII this week in Barron's:
A Cure for Avian Flu?
By ANDREW BARY

GROWING GLOBAL CONCERN about a possible pandemic stemming from avian
flu have put the spotlight on several drug companies that may have
treatments, notably Switzerland's Roche, maker of the highly
sought-after anti-viral, Tamiflu.

AVI BioPharma (ticker: AVII), a little-known U.S. biotechnology firm,
also could be a beneficiary of flu fears because its novel "antisense"
drugs may be effective in combating the flu virus, as well as hepatitis
C and a range of bio-terror threats, including the dreaded Ebola virus.

Antisense drugs potentially offer an elegant antidote to viral diseases
because they're designed to enter cells and eliminate viruses by
preventing their replication. The drugs, which act by blocking critical
viral genetic sequences, may be more potent than anti-virals such as
protease inhibitors, which seek to inhibit a protein needed for viral
replication. AVI's specialty is single-strand RNA viruses, which
include Ebola, hepatitis C and the flu.

Based in Portland, Ore., AVI has developed a drug, now in early
clinical trials, to treat hepatitis C. Its drug to prevent restenosis,
or the reclogging of arteries that can occur after angioplasty, is
undergoing a clinical trial in Europe. The results from the hepatitis C
trial are expected late this year or early in 2006, and the
restenosis-trial data are likely next year.
http://online.barrons.com/article/SB113175890284895503.html?mod=9_0030_b_this_weeks_magazine_main

	Personal Finance Forum Index -> Stocks	All times are GMT
Page 1 of 1